Memory Clinic-Neuropsychology Center, Department of Geriatrics, University Hospital, Basel, Switzerland.
Dement Geriatr Cogn Disord. 2010;29(6):530-3. doi: 10.1159/000314679. Epub 2010 Jul 1.
Our purpose was to measure Abeta(1-42), T-tau and P-tau(181) in the cerebrospinal fluid (CSF) of patients with posterior cortical atrophy (PCA), a presenile dementia likely to represent a variant of Alzheimer's disease (AD).
CSF samples from 34 subjects including 9 patients with PCA, 11 age-matched patients with AD and 14 age-matched cognitively healthy controls were analyzed using commercially available ELISA kits.
The Abeta(1-42), T-tau and P-tau(181) levels in PCA patients differed significantly (p < 0.02) from those in healthy controls but were indistinguishable from subjects with a clinical diagnosis of AD.
High T-tau and P-tau(181) and low Abeta(1-42) levels in PCA - typically observed in AD - indicate that the underlying pathology of PCA is usually AD. If these findings are replicated in PCA patients with autopsy-confirmed AD neuropathology, PCA patients may be eligible for disease-modifying AD treatments.
我们旨在测量皮质后萎缩症(PCA)患者脑脊液(CSF)中的 Abeta(1-42)、T-tau 和 P-tau(181),这种早发性痴呆症可能代表阿尔茨海默病(AD)的一种变异。
使用商业上可用的 ELISA 试剂盒分析了 34 名受试者的 CSF 样本,其中包括 9 名 PCA 患者、11 名年龄匹配的 AD 患者和 14 名年龄匹配的认知健康对照者。
PCA 患者的 Abeta(1-42)、T-tau 和 P-tau(181)水平与健康对照组有显著差异(p < 0.02),但与临床诊断为 AD 的患者无法区分。
PCA 中常见的高 T-tau 和 P-tau(181)以及低 Abeta(1-42)水平表明 PCA 的潜在病理通常是 AD。如果这些发现能够在具有尸检证实的 AD 神经病理学的 PCA 患者中得到复制,那么 PCA 患者可能有资格接受 AD 治疗。